The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 6, 2010, Pages 625-633

  Singal, A G ^a   Rakoski, M O ^a   Salgia, R ^a   Pelletier, S ^a   Welling, T H ^a   Fontana, R J ^a   Lok, A S ^a   Marrero, J A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BILIRUBIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; EXTRAHEPATIC BILE DUCT CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TERTIARY HEALTH CARE;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; BILIRUBIN; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 76449111456     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04218.x     Document Type: Article

References (25)

1. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994 14 : 109 114.
2. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002 51 Suppl 6 : VI1 9.
3. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003 37 : 961 969.
4. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002 2 : 10.
5. Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 2007 19 : 615 617.
6. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005 128 : 620 626.
7. Matull WR, Khan SA, Pereira SP. Re: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2007 99 : 407 author reply 407-8.
8. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006 98 : 873 875.
9. Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005 241 : 693 699 discussion 699-702.
10. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001 234 : 507 517 discussion 517-9.
11. Singal A, Welling TH, Marrero JA. Role of liver transplantation in the treatment of cholangiocarcinoma. Expert Rev Anticancer Ther 2009 9 : 491 502.
12. Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma - a population-based study. Ann Surg Oncol 2008 15 : 600 608.
13. Cheng JL, Bruno MJ, Bergman JJ, Rauws EA, Tytgat GN, Huibregtse K. Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointest Endosc 2002 56 : 33 9.
14. Baton O, Azoulay D, Adam DV, Castaing D. Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm outcomes. J Am Coll Surg 2007 204 : 250 260.
15. Hanazaki K, Kajikawa S, Shimozawa N, et al. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology 2002 49 : 311 316.
16. Murakami Y, Uemura K, Hayashidani Y, et al. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J Surg Oncol 2007 95 : 207 212. (Pubitemid 46310012)
17. Heron DE, Stein DE, Eschelman DJ, et al. Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol 2003 26 : 422 428.
18. Yap CK, Chee EN, Consigliere D, Fock KM. Four year experience with cholangiocarcinoma: a survey of patients, clinical presentation, management and prognosis in two hospitals. Singapore Med J 1992 33 : 235 238.
19. Tagger A, Donato F, Ribero ML, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999 81 : 695 699.
20. Staging AJCoC. Manual for Staging of Cancer, 6th edn. Philadelphia, PA : J.B. Lippincott, 2002.
21. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004 40 : 472 477.
22. Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg 2007 31 : 1256 1263.
23. Weber A, Landrock S, Schneider J, et al. Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma. World J Gastroenterol 2007 13 : 1422 1426.
24. Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 2005 31 : 533 539.
25. Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003 125 : 1355 1363. (Pubitemid 37409755)